Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Last Close
May 23 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-10.09 Insider Own93.13% Shs Outstand9.19M Perf Week-5.95%
Market Cap18.50M Forward P/E- EPS next Y-0.13 Insider Trans-0.01% Shs Float0.80M Perf Month-15.51%
Income-73.22M PEG- EPS next Q-0.36 Inst Own34.07% Short Float3.03% Perf Quarter-17.28%
Sales3.21M P/S5.76 EPS this Y71.85% Inst Trans-12.76% Short Ratio0.67 Perf Half Y-24.94%
Book/sh1.15 P/B1.38 EPS next Y94.76% ROA-113.09% Short Interest0.02M Perf Year-81.20%
Cash/sh2.76 P/C0.57 EPS next 5Y- ROE-178.51% 52W Range1.55 - 9.90 Perf YTD-58.96%
Dividend Est.- P/FCF- EPS past 5Y21.95% ROI-291.53% 52W High-84.04% Beta1.00
Dividend TTM- Quick Ratio3.19 Sales past 5Y57.51% Gross Margin-62.40% 52W Low1.94% ATR (14)0.09
Dividend Ex-Date- Current Ratio3.19 EPS Y/Y TTM27.68% Oper. Margin-1543.65% RSI (14)29.31 Volatility4.29% 4.04%
Employees6 Debt/Eq1.09 Sales Y/Y TTM188.74% Profit Margin-2284.68% Recom3.00 Target Price1.00
Option/ShortNo / Yes LT Debt/Eq0.89 EPS Q/Q23.31% Payout- Rel Volume3.28 Prev Close1.60
Sales Surprise- EPS Surprise-217.07% Sales Q/Q-95.40% EarningsMay 14 BMO Avg Volume36.05K Price1.58
SMA20-11.25% SMA50-11.89% SMA200-49.78% Trades Volume118,334 Change-1.25%
Date Action Analyst Rating Change Price Target Change
Nov-24-21Upgrade Oppenheimer Perform → Outperform $7
Aug-21-19Downgrade Oppenheimer Outperform → Perform
Apr-30-19Initiated Jefferies Buy $18
Dec-13-18Initiated Chardan Capital Markets Buy $20
Mar-19-18Initiated H.C. Wainwright Buy $20
Jan-29-18Initiated Piper Jaffray Overweight $16
Today 03:29PM
May-14-24 01:54PM
Mar-19-24 08:10AM
12:15PM Loading…
Feb-20-24 12:15PM
Feb-09-24 09:41AM
Feb-08-24 04:15PM
Feb-02-24 12:00PM
Jan-16-24 08:47AM
Jan-04-24 07:00AM
Dec-27-23 07:00AM
Dec-07-23 07:00AM
08:55AM Loading…
Nov-14-23 08:55AM
Nov-09-23 07:19AM
Nov-07-23 07:00AM
Nov-02-23 10:00AM
Oct-03-23 04:15PM
Sep-29-23 07:00AM
Sep-28-23 11:15AM
Sep-27-23 12:30PM
Sep-21-23 07:00AM
Sep-19-23 11:00AM
Aug-10-23 08:40AM
Jul-11-23 07:00AM
07:00AM Loading…
Jun-28-23 07:00AM
Jun-27-23 07:00AM
Jun-08-23 06:45AM
Jun-05-23 06:45AM
May-24-23 06:35AM
May-23-23 06:50AM
May-13-23 08:21AM
May-11-23 12:38PM
May-09-23 07:15AM
May-04-23 10:00AM
Apr-28-23 05:12PM
Mar-29-23 07:55AM
Mar-28-23 06:52AM
Mar-20-23 06:55AM
Mar-10-23 08:35AM
Mar-08-23 07:00AM
Mar-07-23 08:35AM
Jan-24-23 06:57AM
Jan-19-23 06:58AM
Jan-17-23 10:00AM
Jan-16-23 12:00PM
Jan-14-23 07:17AM
Jan-05-23 06:58AM
Jan-03-23 06:58AM
Dec-15-22 10:49AM
Dec-04-22 09:27AM
Nov-30-22 04:15PM
Nov-10-22 08:05AM
Oct-18-22 11:15AM
Sep-06-22 07:00AM
Aug-23-22 07:00AM
Aug-11-22 03:50PM
Jul-28-22 07:00AM
Jul-12-22 07:00AM
Jun-29-22 07:00AM
Jun-28-22 07:00AM
Jun-27-22 10:06AM
Jun-21-22 07:00AM
Jun-01-22 07:00AM
May-24-22 07:00AM
May-12-22 10:51AM
May-05-22 07:00AM
Apr-28-22 07:00AM
Apr-26-22 07:00AM
Apr-01-22 07:00AM
Mar-17-22 08:25AM
Mar-10-22 07:00AM
Mar-03-22 07:00AM
Feb-24-22 07:00AM
Feb-08-22 07:00AM
Jan-11-22 08:59AM
Jan-06-22 07:00AM
Dec-24-21 12:00PM
Nov-30-21 10:54AM
Nov-22-21 07:45PM
Nov-18-21 01:04PM
Synlogic, Inc. is a biopharmaceutical company which engages in the discovery and development of synthetic biotic medicines. It focuses on phenylketonuria, enteric hyperoxaluria, immuno-oncology solid tumors, inflammatory bowel disease, and vaccines and other inflammatory programs. The company was founded by James J. Collins and Timothy K. Lu on December 20, 2007 and is headquartered in Cambridge, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Awad AntoineChief Operating OfficerApr 02 '24Sale1.7337264433,859Apr 04 04:00 PM
Dooley Mary BethHead of FinanceApr 02 '24Sale1.7318832515,231Apr 04 04:00 PM